Morgan Stanley’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-404
| Closed | -$1.05K | – | 8470 |
|
|
2025
Q4 | $1.05K | Sell |
404
-6,334
| -94% | -$12.8K | ﹤0.01% | 7354 |
|
|
2025
Q3 | $11.9K | Buy |
6,738
+6,225
| +1,213% | +$9.97K | ﹤0.01% | 6855 |
|
|
2025
Q2 | $713 | Buy |
513
+176
| +52% | +$230 | ﹤0.01% | 7371 |
|
|
2025
Q1 | $332 | Sell |
337
-193,178
| -100% | -$233K | ﹤0.01% | 7419 |
|
|
2024
Q4 | $254K | Sell |
193,515
-3,332
| -2% | -$9.92K | ﹤0.01% | 5700 |
|
|
2024
Q3 | $677K | Sell |
196,847
-98,913
| -33% | -$326K | ﹤0.01% | 5253 |
|
|
2024
Q2 | $976K | Buy |
295,760
+8,231
| +3% | +$29.4K | ﹤0.01% | 4971 |
|
|
2024
Q1 | $1.35M | Sell |
287,529
-378,989
| -57% | -$2.43M | ﹤0.01% | 4807 |
|
|
2023
Q4 | $4.87M | Buy |
666,518
+616,196
| +1,225% | +$3.45M | ﹤0.01% | 4397 |
|
|
2023
Q3 | $608K | Buy |
50,322
+1,018
| +2% | +$10.5K | ﹤0.01% | 5079 |
|
|
2023
Q2 | $522K | Sell |
49,304
-13,599
| -22% | -$140K | ﹤0.01% | 5189 |
|
|
2023
Q1 | $619K | Sell |
62,903
-13,084
| -17% | -$150K | ﹤0.01% | 5131 |
|
|
2022
Q4 | $1.12M | Sell |
75,987
-71,270
| -48% | -$1.07M | ﹤0.01% | 4815 |
|
|
2022
Q3 | $1.79M | Sell |
147,257
-434
| -0.3% | -$5.59K | ﹤0.01% | 4517 |
|
|
2022
Q2 | $2.06M | Buy |
147,691
+64,710
| +78% | +$762K | ﹤0.01% | 4517 |
|
|
2022
Q1 | $1.18M | Buy |
82,981
+48,091
| +138% | +$713K | ﹤0.01% | 4877 |
|
|
2021
Q4 | $736K | Sell |
34,890
-52,462
| -60% | -$1.24M | ﹤0.01% | 5294 |
|
|
2021
Q3 | $2.29M | Sell |
87,352
-45,376
| -34% | -$1.47M | ﹤0.01% | 4460 |
|
|
2021
Q2 | $4.14M | Buy |
132,728
+70,112
| +112% | +$2.3M | ﹤0.01% | 3978 |
|
|
2021
Q1 | $1.92M | Buy |
62,616
+23,820
| +61% | +$809K | ﹤0.01% | 4285 |
|
|
2020
Q4 | $1.33M | Buy |
38,796
+17,261
| +80% | +$516K | ﹤0.01% | 4482 |
|
|
2020
Q3 | $663K | Buy |
21,535
+9,114
| +73% | +$241K | ﹤0.01% | 4484 |
|
|
2020
Q2 | $385K | Buy |
+12,421
| New | +$399K | ﹤0.01% | 4734 |
|
Morgan Stanley's RPTX Position: Q1 2026 in Review
Morgan Stanley sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 404 shares — an estimated $1.05K sold.
Morgan Stanley first reported a position in RPTX in Q2 2020 and held it in 23 quarters. The position peaked at $4.87M in Q4 2023. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Morgan Stanley reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 404 Repare Therapeutics shares in Q1 2026, an estimated $1.05K.
- Morgan Stanley first reported a position in Repare Therapeutics in Q2 2020 and held it in 23 quarters.
- Morgan Stanley's Repare Therapeutics position peaked at $4.87M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.